A pilot study of 64Cu-DOTA-trastuzumab-PET in six patients with primary or metastatic HER2-positive breast cancer demonstrated safety and feasibility of this agent, as well, including for evaluation of HER2-postive brain metastases [120]. This evidence concerns the gene ERBB2 and breast carcinoma.